Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 243

Sort by

Sort Order Select

Journal Articles

Prognostic value of immunoparesis, lymphopenia, high serum ferritin, and suppression of the non-involved serum free light chains (niFLC) in relapsed and refractory multiple myeloma patients (RRMM) receiving bispecific antibodies

Blood (2025) 146 (Supplement 1): 5772.

https://doi.org/10.1182/blood-2025-5772

Published: 2025

Journal Articles

Patient preferences and factors affecting patient treatment decisions for chronic lymphocytic leukemia (CLL) in Japan

Hirohiko Shibayama, Junji Suzumiya, Kuniharu Matsuno, Kazuki Kiyose, Mei Xue, Yan Meng, Todor I. Totev, Zhuo Chen, Keri Yang, Sikander Ailawadhi

Blood (2025) 146 (Supplement 1): 4406.

https://doi.org/10.1182/blood-2025-4406

Published: 2025

Journal Articles

Post-transplant cyclophosphamide significantly reduces early non-relapse mortality following allogeneic hematopoietic cell transplantation

Emily Wolf, Megan Melody, Athanasios Tsalatsanis, Suhaib El Khatib, Yenny Moreno Vanegas, Annette Velez-Tirado, Zaid Abdel Rahman, Denise Gococo-Benore, James Foran, Ernesto Ayala, Madiha Iqbal, Ricardo Parrondo, Sikander Ailawadhi, Hemant Murthy, Vivek Roy, Mohamed Kharfan-Dabaja

Blood (2025) 146 (Supplement 1): 7820.

https://doi.org/10.1182/blood-2025-7820

Published: 2025

Journal Articles

Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study

Blood (2025) 146 (Supplement 1): 5819.

https://doi.org/10.1182/blood-2025-5819

Published: 2025

Journal Articles

S2005: A phase II randomized study comparing ibrutinib and rituximab (IR) VS. venetoclax and rituximab (VR) in previously untreated waldenstrom's macroglobulinemia (WM) / lymphoplasmacytic lymphoma (LPL).

Sikander Ailawadhi, Divaya Bhutani, Antje Hoering, Adam Rosenthal, J Christine Ye, Prashant Kapoor, Saad Usmani, Manisha Bhutani, S. Vincent Rajkumar, Paul Gater, Robert Orlowski

Blood (2025) 146 (Supplement 1): 1840.

https://doi.org/10.1182/blood-2025-1840

Published: 2025

Journal Articles

Health care resource utilization in patients with multiple myeloma receiving bispecific antibody therapy with teclistamab: A Medicare claims database analysis in the US

Sikander Ailawadhi, Thomas Delea, Olivier Humblet, Timothy Inocencio, Mengying Li, Alexandra Bryan, Aaron Moynahan, Glenn Kroog, Christian Hampp, Michelle Little, Qiufei Ma

Blood (2025) 146 (Supplement 1): 3975.

https://doi.org/10.1182/blood-2025-3975

Published: 2025

Journal Articles

Home administration of isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study

María-Victoria Mateos, Silvia Ling, Claudio Cerchione, Peter Rajnics, Massimo Offidani, Fredrik Schjesvold, Masaki Ri, Satoshi Ito, Florence Suzan Teisserenc, Rick Zhang, Maya Stefanova-Urena, Sikander Ailawadhi

Blood (2025) 146 (Supplement 1): 4044.

https://doi.org/10.1182/blood-2025-4044

Published: 2025

Journal Articles

Impact of race and socioeconomics on access to T-cell engaging therapy in US patients with relapsed/refractory multiple myeloma (RRMM)

Yvonne Efebera, Yelak Biru, Jeff O'Donnell, Kevin Brigle, Rebecca Davies, Anthony Greenwood, Jack Watkins, Katie Quinn, Isabel Perez-Cruz, James Farrell, Sikander Ailawadhi

Blood (2025) 146 (Supplement 1): 2813.

https://doi.org/10.1182/blood-2025-2813

Published: 2025

Journal Articles

Evaluating patient preferences for chronic lymphocytic leukemia (CLL) in Korea: A discrete choice experiment

Byung Woo Yoon, Suhyeon Lee, Mei Xue, Yan Meng, Dominic Pilon, Fengyi Jiang, Keri Yang, Sikander Ailawadhi

Blood (2025) 146 (Supplement 1): 7923.

https://doi.org/10.1182/blood-2025-7923

Published: 2025

Journal Articles

Real-world (RW) outcomes of newly diagnosed multiple myeloma (NDMM) patients (pts) treated with front-line daratumumab (dara), bortezomib (bor), lenalidomide (len) and dexamethasone (dex) (DVRd)

Blood (2025) 146 (Supplement 1): 4585.

https://doi.org/10.1182/blood-2025-4585

Published: 2025

Journal Articles

National cross-sectional Study to explore current state of patient awareness of multiple myeloma (MM) disease basics and its management: Identifying gaps and associations

Kenyot'a Russell, Saurav Das, Dhaani Ailawadhi, Jayla Mondy, Ricardo Parrondo, Taimur Sher, Vivek Roy, Andre Fernandez, Caitlin Flott, Asher Chanan-Khan, Sikander Ailawadhi

Blood (2025) 146 (Supplement 1): 4587.

https://doi.org/10.1182/blood-2025-4587

Published: 2025

Journal Articles

Characteristics and treatment patterns of nontransplanted patients with newly diagnosed multiple myeloma treated with daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) or daratumumab, lenalidomide, and dexamethasone (DRd) in the frontline setting

Sikander Ailawadhi, Xin Yin, Eric Chinaeke, Jinghua He, Laura Clark, Annelore Cortoos, Rohan Medhekar

Blood (2025) 146 (Supplement 1): 6359.

https://doi.org/10.1182/blood-2025-6359

Published: 2025

Journal Articles

Real-world comparison of progression-free and overall survival between idecabtagene vicleucel (ide-cel) and teclistamab in triple-class exposed relapsed/refractory multiple myeloma

Krina Patel, Jenny Chen, Devender Dhanda, Kevin Towle, Luciano Costa, Sikander Ailawadhi, Saad Usmani, Sridevi Rajeeve, Yi Lin, Sichen Liu, Shannon Cope, Surbhi Sidana

Blood (2025) 146 (Supplement 1): 4563.

https://doi.org/10.1182/blood-2025-4563

Published: 2025

Journal Articles

KarMMa-3 subgroup analysis in older patients with relapsed/refractory multiple myeloma treated with idecabtagene vicleucel

Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay Nooka, Salomon Manier, Shinsuke Iida, Sophie Hello, Devender Dhanda, Prachi Ghodke, Martina Raggi, Roland Marion Gallois, Jaclyn Davis, Paula Rodriguez-Otero

Blood (2025) 146 (Supplement 1): 2297.

https://doi.org/10.1182/blood-2025-2297

Published: 2025

Journal Articles

Effect of pre-allogeneic HCT splenic irradiation on post-transplant engraftment and outcomes in patients with myelofibrosis: A single-center experience

Yenny Moreno Vanegas, Ahmed Abdelhakeem, Madiha Iqbal, Vivek Roy, Ricardo Parrondo, Sikander Ailawadhi, Ernesto Ayala, James Foran, Jennifer Peterson, Bradford Hoppe, Mohamed Kharfan-Dabaja, Hemant Murthy

Blood (2025) 146 (Supplement 1): 5984.

https://doi.org/10.1182/blood-2025-5984

Published: 2025

Journal Articles

Prophylactic dexamethasone to reduce risk of cilta-cel associated immune effector cell delayed neurotoxicity

Blood (2025) 146 (Supplement 1): 5953.

https://doi.org/10.1182/blood-2025-5953

Published: 2025

Journal Articles

Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome

Blood (2025) 146 (Supplement 1): 5812.

https://doi.org/10.1182/blood-2025-5812

Published: 2025

Journal Articles

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Aaron S. Rosenberg, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji Kumar, Angela Dispenzieri, Sagar Lonial, Brian G. M. Durie, Paul G. Richardson, Saad Z. Usmani, Antje Hoering, Robert Z. Orlowski

Blood (2025) 145 (1): 75–84.

https://doi.org/10.1182/blood.2024025939

Published: 2025

Includes: Supplemental data

Journal Articles

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Blood (2024) 144 (23): 2389–2401.

https://doi.org/10.1182/blood.2024024582

Published: 2024

Includes: Supplemental data

Journal Articles

Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma Retreated with Daratumumab in Real-World Clinical Practice in the USA

Sikander Ailawadhi, Sarah M. Larson, Shannon Ferrante, Nicole Rafalko, Niodita Gupta-Werner, Jennifer S. Harper, Rohan Medhekar, Marjohn Armoon, Annelore Cortoos, Shuchita Kaila, Shebli Atrash

Blood (2024) 144 (Supplement 1): 2381.

https://doi.org/10.1182/blood-2024-199085

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic value of immunoparesis, lymphopenia, high serum ferritin, and suppression of the non-involved serum free light chains (niFLC) in relapsed and refractory multiple myeloma patients (RRMM) receiving bispecific antibodies

Patient preferences and factors affecting patient treatment decisions for chronic lymphocytic leukemia (CLL) in Japan

Post-transplant cyclophosphamide significantly reduces early non-relapse mortality following allogeneic hematopoietic cell transplantation

Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study

S2005: A phase II randomized study comparing ibrutinib and rituximab (IR) VS. venetoclax and rituximab (VR) in previously untreated waldenstrom's macroglobulinemia (WM) / lymphoplasmacytic lymphoma (LPL).

Health care resource utilization in patients with multiple myeloma receiving bispecific antibody therapy with teclistamab: A Medicare claims database analysis in the US

Home administration of isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study

Impact of race and socioeconomics on access to T-cell engaging therapy in US patients with relapsed/refractory multiple myeloma (RRMM)

Evaluating patient preferences for chronic lymphocytic leukemia (CLL) in Korea: A discrete choice experiment

Real-world (RW) outcomes of newly diagnosed multiple myeloma (NDMM) patients (pts) treated with front-line daratumumab (dara), bortezomib (bor), lenalidomide (len) and dexamethasone (dex) (DVRd)

National cross-sectional Study to explore current state of patient awareness of multiple myeloma (MM) disease basics and its management: Identifying gaps and associations

Characteristics and treatment patterns of nontransplanted patients with newly diagnosed multiple myeloma treated with daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) or daratumumab, lenalidomide, and dexamethasone (DRd) in the frontline setting

Real-world comparison of progression-free and overall survival between idecabtagene vicleucel (ide-cel) and teclistamab in triple-class exposed relapsed/refractory multiple myeloma

KarMMa-3 subgroup analysis in older patients with relapsed/refractory multiple myeloma treated with idecabtagene vicleucel

Effect of pre-allogeneic HCT splenic irradiation on post-transplant engraftment and outcomes in patients with myelofibrosis: A single-center experience

Prophylactic dexamethasone to reduce risk of cilta-cel associated immune effector cell delayed neurotoxicity

Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma Retreated with Daratumumab in Real-World Clinical Practice in the USA

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only